Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors. (Q30377161)

21 June 2017

title

Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors. (English)

1 reference

21 June 2017

0 references

1

Gaston De Serres

1 reference

21 June 2017

3

Danuta M Skowronski

1 reference

21 June 2017

Isabelle Rouleau

2

1 reference

21 June 2017

Manale Ouakki

4

1 reference

21 June 2017

Kevin Lacroix

5

1 reference

21 June 2017

Fernand Bédard

6

1 reference

21 June 2017

Eveline Toth

7

1 reference

21 June 2017

Monique Landry

8

1 reference

21 June 2017

Nicolas Dupré

9

1 reference

21 June 2017

language of work or name

English

0 references

publication date

22 July 2015

1 reference

21 June 2017

1 reference

21 June 2017

volume

33

1 reference

21 June 2017

issue

36

1 reference

21 June 2017

page(s)

4464-4471

1 reference

Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Guillain-Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Acute encephalomyelitis syndromes associated with H1N1 09 influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Bithalamic compromise in acute disseminated encephalomyelitis following H1N1 influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

An adverse event following 2009 H1N1 influenza vaccination: a case of acute disseminated encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Encephalitis after vaccination against H1N1 influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Adverse neurologic reactions after both doses of pandemic H1N1 influenza vaccine with optic neuritis and demyelination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

[National Campaign of Vaccination against the flu A (H1N1)v: National Follow-up of Pharmacovigilance]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Adverse events following pandemic influenza vaccine Pandemrix® reported in the French military forces--2009-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Development and testing of a neuropathic pain screening questionnaire: ID Pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Neuropathic pain in breast cancer survivors: using the ID pain as a screening tool

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

An inventory for measuring clinical anxiety: psychometric properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

The PHQ-9: validity of a brief depression severity measure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

The somatosensory amplification scale and its relationship to hypochondriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Medically unexplained cutaneous sensory symptoms may represent somatoform dissociation: an empirical study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

The reporting sensitivities of two passive surveillance systems for vaccine adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.028

10.1016/J.VACCINE.2015.07.028

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference